Sort by
Refine Your Search
-
Program
-
Field
-
), is internationally recognized for its pioneering research in radiopharmaceutical chemistry, and targeted radionuclide therapy. The research group of Prof. Roger Schibli develops innovative
-
, but to drive innovative research and achieve decisive progress. Further details on NCCR Genesis are available on its website https://nccr-genesis.ch . Job description The successful candidate will
-
-invasive targeted drug delivery to the brain. Our laboratory recently developed a novel focused ultrasound-mediated targeted drug delivery platform, published in Nature Communications (https://www.nature.com
-
via email or postal services will not be considered. We will get in touch with you after 2 - 3 weeks following the submission deadline. About ETH ZürichETH Zurich is one of the world’s leading
-
from proof-of-concept toward clinical translation. Successful candidates will further develop the technology, investigate its therapeutic potential for neurological disorders, perform preclinical